Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

MEDI-528

Known as: Anti-IL9 Monoclonal Antibody MEDI-528, MEDI 528, MEDI-528, anti-IL-9 antibody 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
From bench to bedside: Therapeutic potential of interleukin-9 in the treatment of asthma.
Initially identified as a T cell and mast cell growth factor, interleukin (IL)-9 has long been recognized as an important… 
  • table I
  • table II
2017
2017
Targeting cytokines in asthma therapy: could IL-37 be a solution?
  • M. Wegmann
  • Expert review of respiratory medicine
  • 2017
  • Corpus ID: 27115523
Patients suffering from bronchial asthma display a number of symptoms including productive coughing, wheezing, chest tightness… 
Highly Cited
2013
Highly Cited
2013
A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma
BackgroundPreclinical studies suggest that interleukin-9 may be a central mediator in the development and maintenance of airway… 
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Highly Cited
2011
Highly Cited
2011
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma
BackgroundInterleukin-9 (IL-9)-targeted therapies may offer a novel approach for treating asthmatics. Two randomized placebo… 
  • figure 1
  • table 1
  • table 3
  • table 2
  • table 4
2010
2010
MEDI-528, an anti-IL-9 humanized antibody for the treatment of asthma.
  • S. Antoniu
  • Current opinion in molecular therapeutics
  • 2010
  • Corpus ID: 23088594
In development by MedImmune LLC, under license from Genaera Corp, MEDI-528 is an injectable, humanized mAb against IL-9 for the… 
2010
2010
Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2A Study To Evaluate The Effect Of A Humanized Interleukin-9 Monoclonal Antibody (MEDI-528) On Exercise-induced Bronchospasm
2010
2010
Monoclonal antibody therapy directed against interleukin-9: MEDI-528
Highly Cited
2009
Highly Cited
2009
Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.
BACKGROUND Interleukin-9 (IL-9) is involved in pathogenic aspects of the asthmatic response, including induction of the… 
  • table I
  • figure 1
  • table II
  • figure 2
  • figure 3
2009
2009
A candidate gene association study of 77 polymorphisms in migraine.
UNLABELLED Population-based studies have established an association between migraine and cardiovascular disease (CVD). We sought… 
  • table 1
  • table 2
  • table 2
  • table 3
2007
2007
A SINGLE DOSE OF MEDI-528, A MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-9, IS WELL TOLERATED IN MILD AND MODERATE ASTHMATICS IN THE PHASE II TRIAL MI-CP-138
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE